Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
New Microbiol ; 38(1): 113-8, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25742155

ABSTRACT

This report describes a case of meningitis caused by Listeria monocytogenes in a stem cell transplant recipient on immunosuppressive therapy for cutaneous chronic graft-versus host disease. A 59-year-old woman had undergone allogeneic stem cell transplantation (from a matched unrelated donor) 13 months previously for chronic lymphocytic leukemia. She was on regular hematologic follow-up. Though her previous malignancy has been in remission, she was immunosuppressed due to the pharmacological treatment. We describe a meningitis caused by a typical food-borne pathogen, dangerous in patients with impaired cell-mediated immunity. Moreover the bacterium had a multidrug resistance, a rare characteristic in clinical listeriosis. Rapid diagnosis and treatment are key factors in these cases. We chose ampicillin and rifampicin that allowed a complete resolution of the clinical manifestations.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Listeria monocytogenes/isolation & purification , Meningitis, Listeria/microbiology , Anti-Bacterial Agents/therapeutic use , Female , Humans , Immunocompromised Host , Listeria monocytogenes/genetics , Meningitis, Listeria/drug therapy , Meningitis, Listeria/etiology , Meningitis, Listeria/immunology , Middle Aged , Transplantation, Homologous/adverse effects
2.
Am J Obstet Gynecol ; 188(2): 313-7, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12592232

ABSTRACT

OBJECTIVE: The study was undertaken to evaluate whether raloxifene influences endothelium-dependent and endothelium-independent vasodilatation in women. STUDY DESIGN: In a double-blind, placebo-controlled randomized study, 30 osteopenic but otherwise healthy postmenopausal women received either placebo (n = 15 with one dropout) or raloxifene (60 mg/d, n = 15). Brachial artery flow-mediated endothelium-dependent and endothelium-independent vasodilatation was evaluated by ultrasound before and after 6 months of treatment, along with lipid and glucose metabolism. Endothelium-dependent dilatation was evaluated after a 4-minute block of artery blood flow through a cuff insufflated at suprasystolic blood pressure. Endothelium-independent vasodilatation was evaluated after sublingual nitroglycerin administration (400 microg). RESULTS: Placebo did not modify any vascular or metabolic parameter. Raloxifene significantly decreased low-density lipoprotein levels (4.60 +/- 0.18 mmol/L vs 3.94 +/- 0.30 mmol/L, P <.015) but did not modify endothelium-dependent (21.6% +/- 4.6% vs 20.6% +/- 3.8%) or endothelium-independent vasodilatation (26.3% +/- 5.1% vs 32.0% +/- 5.5%). CONCLUSION: Prolonged administration of raloxifene does not influence endothelium-dependent and endothelium-independent vasodilatation of osteopenic but otherwise healthy postmenopausal women.


Subject(s)
Blood Circulation/physiology , Endothelium, Vascular/physiopathology , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/physiopathology , Raloxifene Hydrochloride/therapeutic use , Selective Estrogen Receptor Modulators/therapeutic use , Vasodilation/drug effects , Double-Blind Method , Female , Humans , Lipoproteins, LDL/antagonists & inhibitors , Lipoproteins, LDL/blood , Middle Aged , Vasodilation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...